Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.
Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.
复制标题
程序性死亡配体 1 的表达与骨髓肉瘤患者的不良预后相关。
DOI：
10.1002/hon.2506
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Ohshima K.
中科院分区：
文献类型：
--
作者：
Kawamoto K;Miyoshi H;Suzuki T;Kiyasu J;Yokoyama S;Sasaki Y;Sone H;Seto M;Takizawa J;Ohshima K.
骨髓肉瘤是一种罕见的疾病，是一种未成熟骨髓细胞的髓外肿瘤。目前已知程序性死亡1（PD-1）/程序性死亡配体1（PD-L1）通路抑制宿主抗肿瘤反应，并且这些产物在各种恶性肿瘤的肿瘤细胞和肿瘤浸润细胞上表达。然而，关于MS中肿瘤细胞和肿瘤微环境细胞上PD-1/PD-L1表达的意义知之甚少。为了研究MS中PD-1/PD-L1表达的临床病理学意义，我们通过免疫组化分析了98例患者。其中，10.2%的病例具有PD-L1阳性的肿瘤细胞（nPD-L1+）。然而，nPD-L1+的发生率<5%（范围：0.27 - 2.97%）。另一方面，在37.8%的病例中观察到肿瘤微环境（miPD-L1+）中1个或多个基质细胞上的PD-L1表达。由于所有nPD-L1+病例表达PD-1的肿瘤细胞少于5%，因此我们比较了miPD-L1+和miPD-L1-组。miPD-L1+状态与表达PD-1的肿瘤浸润淋巴细胞（PD-1+ TIL;P= 0.0229）数量之间存在相关性。发现miPD-L1+与较差的总生存期和无进展生存期相关（分别为P= 0.00392，P = 0.00261）。多变量分析也证实miPD-L1+是一个独立的不良预后因素。总之，我们的研究表明，阻断PD-1/PD-L1通路的免疫治疗可能会改善MS的临床结局。
Myeloid sarcoma (MS) is a rare condition and is an extramedullary tumour of immature myeloid cells. It is now known that the programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) pathway suppresses the host antitumor responses and that these products are expressed on both tumour cells and tumour‐infiltrating cells in various malignancies. However, little is known about the significance of PD‐1/PD‐L1 expression on tumour cells and tumour microenvironmental cells in MS. To investigate the clinicopathological significance of PD‐1/PD‐L1 expression in MS, we analyzed 98 patients by immunohistochemistry. Of these, 10.2% of cases had neoplastic tumour cells positive for PD‐L1 (nPD‐L1+). However, the rate of nPD‐L1+was <5% (range: 0.27 to 2.97%). On the other hand, PD‐L1 expression on 1 or more of stromal cells in the tumour microenvironment (miPD‐L1+) was observed in 37.8% of cases. Because all nPD‐L1+cases expressed PD‐1 on less than 5% of tumour cells, we compared the miPD‐L1+and miPD‐L1−groups. There was a correlation between miPD‐L1+status and the number of PD‐1‐expressing tumour ‐infiltrating lymphocytes (PD‐1+TILs;P= .0229). miPD‐L1+was found to be associated with poorer overall survival and progression‐free survival (P= .00392,P= .00261, respectively). Multivariate analysis also confirmed miPD‐L1+to be an independent poor prognostic factor. In conclusion, our study indicated that the immunotherapy blocking the PD‐1/PD‐L1 pathway may improve the clinical outcome of MS.